Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Other Non-Current Assets (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Other Non-Current Assets for 3 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 12.51% to $7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 million, a 12.51% increase, with the full-year FY2025 number at $7.6 million, up 12.51% from a year prior.
  • Other Non-Current Assets was $7.6 million for Q4 2025 at Nuvation Bio, up from $7.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.6 million in Q4 2025 to a low of $138000.0 in Q1 2023.
  • A 3-year average of $3.2 million and a median of $1.1 million in 2024 define the central range for Other Non-Current Assets.
  • Biggest YoY gain for Other Non-Current Assets was 1454.58% in 2025; the steepest drop was 12.51% in 2025.
  • Nuvation Bio's Other Non-Current Assets stood at $587000.0 in 2023, then skyrocketed by 1051.79% to $6.8 million in 2024, then rose by 12.51% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Other Non-Current Assets are $7.6 million (Q4 2025), $7.5 million (Q3 2025), and $6.6 million (Q2 2025).